MDxHealth SA (“MDxHealth”) markets two proprietary, differentiated tests (SelectMDx and ConfirmMDx) that optimize the care of patients with prostate cancer.
SelectMDx is a urine test that tells a doctor whether to do a prostate biopsy after a high prostate specific antigen test (PSA). ConfirmMDx is a tissue test used to confirm a negative prostate biopsy.
The tests help clinicians identify cancer earlier and avoid unnecessary biopsies in patients that are free of cancer. It is widely recognized that prostate biopsies are overused, resulting in unnecessary costs and complications.
MDxHealth has offices in Herstal, Belgium and Irvine, California, USA. Eric Bednarski and Kyle Dempsey represent MVM's investment in the company.
Mr. Michael McGarrity
Chief Executive Officer
CAP Business Center
Rue d’Abhooz, 31
US Office and Laboratory
15279 Alton Parkway
Irvine, CA 92618 U.S.